BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 3, 2023
See today's BioWorld MedTech
Home
» FDA formalizes class II risk designation for containment systems for power morcellators
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA formalizes class II risk designation for containment systems for power morcellators
Nov. 23, 2021
By
Mark McCarty
No Comments
The FDA has continued a series of device risk classifications with the formal announcement that general containment systems used with power morcellators will henceforth be deemed class II, moderate-risk devices.
BioWorld MedTech
Regulatory
U.S.
FDA